selol

Selenitetriglycerides is an oryginal Polish discovery. It has no equivalents in treatment.

SELOL it is a mixture of over 30 selenitetriglycerides obtained by incorporating selenic acid (IV) into molecules of fatty acids from plant oil. The mixture has been given a name - SELOL.

The use of selenitetriglycerides in treatment may contribute to the decrease in the risk of lifestyle diseases such as: cancers, cardiovascular diseases, multiple sclerosis, diabetes, rheumatic diseases, Parkinson’s disease and many other diseases which result from oxidative stress and the disruption of natural redox state of cells caused by a low concentration of glutathione.
It is the only preparation in the world that can increase the concentration of glutathione in brain cells with absolute safety.
Selol neutralizes the side effects of toxic chemotherapeutics, i.e. it changes their metabolism. It is active in the first and the second phase of the metabolism of xenobiotics. It shows synergistic and additive effect with chemotherapeutics.
Selol neutralizes the side effects of toxic chemotherapeutics, i.e. it changes their metabolism. It is active in the first and the second phase of the metabolism of xenobiotics. It shows synergistic and additive effect with chemotherapeutics.
Selol also shows chelation properties- it removes heavy and light metals from the body and prevents the accumulation of strontium, mercury, cadmium, lead, caesium etc. That often eliminates the cause of many diseases, especially neoplasms.
In the first phase of metabolism, it shows strong prooxidative and anticancer activity, while in the second phase, after the reduction with glutathione, it shows antioxidative and restorative activity in cell membranes, DNA and other parts of the cell that might have been damaged by free radicals in the first phase of Selol’s activity.
It has been proven years ago that excess in antioxidants is harmful, especially in cancer disease, and using high doses of selenium(II) compounds can shorten the life span. Mammals are unable to deal with high doses of selenium(II). They are incapable of metabolizing and excreting it quickly enough.
There is a need or selenium (IV) compounds metabolized to selenodiglutathione (compound of strong anticancer activity) and selenides (H2Se), which substitute the serine – OH group for SeH. An active form of selenocysteine is formed, and it is quickly incorporated into the active sites of selenoenzymes. After the attack of free oxygen radicals resulting from Se(IV) administration, comes a period of repairing all damages done by the reactive oxygen species, but only in healthy cells. Gamma-glutamylcysteine synthetase is blocked in cancer cells (total reduction in glutathione production). cancer cells are deprived of their first, most important line of antioxidative defense. in addition, cysteine dioxygenase is blocked. Cysteine is accumulated in cancer cells. All proteins are cysteinylated and the cells are destroyed.
Based on the results of toxicity tests conducted in rats (examinations clinical, clinical-chemical, post-mortem, histophatological) with repeated 90-day oral administration of the test material in different doses: 2, 8 and 32 mg of Se (IV) / kg body mass, the no-observed-adverse-effect level (NOAEL) was 2 mg / kg b.m.
We have never recorded the slightest damage in organs during the treatment with selenitetriglycerides.
The therapeutic dose used in cancer treatment is 1-2 mg of Se(IV)/ kg body mass.
The selenitetriglycerides described above, that is, organic compounds of selenium (IV), when used in cancer treatment in doses 2000 times higher, destroy cancer cells in a natural manner- by apoptosis, causing no harm to normal cells.